Semax Dosage: A Complete and Reliable Guide

What is a reasonable starting dose of Semax?

Let's be honest about something important before we get to the numbers: there is no officially established, FDA-approved starting dose of Semax for humans, as Semax has never gone through Western clinical trial dosing protocols.

What exists is an extensive body of Russian clinical and animal research providing a reasonable picture of the doses that have actually been tested and used. In published Russian clinical literature, nasal doses for stroke patients have ranged from 12 to 18 milligrams per day [1], while many of the smaller animal behavioural and cognitive studies have used much lower doses, in the range of 0.05–0.5 milligrams per kilogram of body weight [2], [3]. This is a rather wide range, and the appropriate dose really depends on what one is trying to achieve and to which body of research one is referring.

For someone new to using Semax, the general rule seen in research — and followed by most people in the nootropic communities — is to start with a low dose and observe the body's reaction before increasing it. Animal studies consistently show that Semax does not follow a simple „the more, the better” pattern. In one anti-hypoxic study, the effects of Semax actually followed a bell-shaped curve rather than a straight line — efficacy increased with the dose up to a certain point and then began to decrease at higher doses [4]. This is an important detail because it tells us that increasing the dose does not necessarily provide more benefits, and finding your own lower effective range matters more with Semax than with some other compounds.

What counts as a minimum effective dose?

Based on available research, even quite small doses elicited measurable effects. In rat studies analysing BDNF and gene expression changes, a single intranasal dose of just 50 micrograms per kilogram of body weight was sufficient to induce a significant increase in hippocampal BDNF [5]. Translating to human conditions, such microgram-per-kilogram dosing translates to a relatively small total dose. However, it must be stressed that translating animal doses to human doses is not a simple multiplication and should not be treated as such.

This practically tells us that Semax does not seem to require large amounts to begin eliciting biological effects. Early Russian clinical works on cognitive and attentional benefits in healthy individuals used doses ranging from 0.015–0.050 milligrams per kilogram of body weight, administered intranasally [6]. For an average adult, this translates to a range of approximately 1–4 milligrams. This provides a reasonable benchmark for a minimum effective dose based on historical clinical work, although no formal dose-ranging study has established an exact threshold.

How to increase the dose over time?

If starting from scratch, the most sensible approach, based on available pharmacology, is to begin at the lower end of the studied range, give the body a few days to show how it responds, and only gradually increase the dosage if needed — rather than jumping straight into the higher doses used in stroke clinical protocols. Stroke patients receiving 12–18 milligrams daily [1] were dealing with a serious medical condition under physician’s care, and that context simply does not apply to an individual using Semax for general cognitive support.

A stepwise approach also makes sense, given that Semax's effects build over time at the gene expression level, rather than appearing instantaneously. Researchers tracking BDNF and NGF gene expression after a single dose found a complex, changing pattern in the hours that followed – levels rose and fell at different time points in different brain regions [7]. This tells us that Semax performs something dynamic and ongoing in the body, rather than simply providing a one-off boost. Allowing yourself to observe your own reaction over a few days, rather than rapidly escalating, fits this slower, more layered biological picture.

Is there a reliable Semax dosage calculator?

There is no official, scientifically validated Semax dosing calculator, and any calculator found online is built on extrapolated animal data and user-reported practices, rather than human dose-finding studies.

The basic mathematics behind reconstitution and dosing are simple, however, once the concentration and target dose are established. If a vial contains, for instance, 10 milligrams of Semax powder, and is reconstituted with 2 millilitres of bacteriostatic water, this yields a concentration of 5 milligrams per millilitre or 5000 micrograms per millilitre. From there, calculating how many millilitres equals a 300 microgram dose is simple division. What no calculator can responsibly determine, however, is what dose anyone should actually aim for, as that number simply has not been established by controlled human trials.

What does the Semax dosage table actually look like?

Below is a practical summary of dosage ranges that have actually appeared in published studies, ordered by context. It is worth reiterating that none of these represent an officially approved dosing protocol for humans – they reflect what has been studied and used under specific research and clinical conditions.

This range is broad, as the appropriate dose is indeed heavily dependent on what condition is being treated and how severe it is. Stroke recovery protocols are at the upper end of the scale, as they are treating a severe neurological injury, whereas general cognitive studies in healthy animals and humans focus on the lower end.

How many puffs per dose does this translate to?

This depends entirely on the concentration of the specific product, as a single spritz is not a standardised unit – it varies depending on the design of the bottle and the spray nozzle. As a general reference point, a standard actuation of a nasal spray pump typically delivers approximately 100 microlitres, although this can vary.

For the 1% solution — 10 milligrams per millilitre, or 10,000 micrograms per millilitre — a single 100-microlitre spray would deliver approximately 1,000 micrograms, or 1 milligram. With a 0.1% solution — 1 milligram per millilitre — the same volume of spray would deliver approximately 100 micrograms.

This is precisely why concentration is so important for dosage accuracy. The same number of sprays can mean drastically different actual doses depending on the strength of the solution being used. Every person using a nasal spray product needs to know both the concentration of their particular bottle and the volume of a single actuation from their specific nozzle to have realistic confidence in their dose – which partly explains why nasal administration, while convenient, is indeed less precise than injection.

What does the Semax and Selank combination dosage table look like?

There are no published clinical trials establishing a formal dosing schedule for Semax and Selank in combination, as no controlled studies have tested them as a combined protocol.

What exists in practice is simply dosing each peptide according to its individually researched range, administered together or at different times of the day. Selank's own research typically used doses in a similar microgram-to-low-milligram range as Semax [12], and in Russian clinical use, both peptides are typically formulated and dosed as separate nasal solutions rather than as a single combined product. Anyone combining them is essentially imposing two individually dosed protocols rather than following any validated shared dosing scheme.

How often should Semax actually be taken?

Once daily is the frequency most consistently observed in both clinical and animal studies and aligns well with what is known about Semax's duration of effect. Early Russian clinical work specifically noted that the cognitive and performance benefits of a single intranasal dose lasted approximately 20–24 hours [6], which naturally supports a once-daily dosing regimen, rather than multiple doses spread throughout the day. If the effects of a morning dose are still significantly present 20 or more hours later, there is no obvious pharmacological reason to dose again before this window closes.

However, some clinical protocols did involve administration spread throughout the day rather than a single dose. In post-stroke rehabilitation studies, a total daily dose of 6000 micrograms was delivered as part of structured 10-day treatment courses [10], and the precise timing within the day—a single dose versus divided doses—was not always detailed in published summaries. The practical takeaway is that once-daily dosing has a solid basis in the available evidence, but dividing the daily dose into two smaller administrations is also consistent with how it has been used clinically in some contexts.

Can Semax be taken daily on a continuous basis?

This is truly one of the more important open questions in Semax literature, and the honest answer is that data on long-term continuous use simply doesn't exist.

What exists is a strong pattern in Russian clinical practice of using Semax in specific courses rather than indefinite daily use – typically 10-day treatment blocks with a break, sometimes repeated after a few weeks [10]. It is this cyclical approach, rather than continuous daily use stretched over months or years, which is the model with the greatest clinical precedent behind it.

There is also a sensible biological argument for this cyclical approach. Given that a substantial portion of Semax's benefits seem to stem from inducing changes in gene expression and neurotrophin production—rather than from the mere continuous occupancy of the receptor itself [5], [7]—it is plausible that intermittent, cyclical dosing allows these biological cascades to fully unfold and then reset, rather than potentially blunting the response through constant, uninterrupted stimulation. This is reasoning from an available mechanism, rather than a directly tested outcome, but it helps explain why the cyclical approach has become standard practice, as opposed to indefinite daily use.

What is a reasonable dosing regimen to use?

Based on how Semax has actually been used in existing studies, a sensible structure would be: a single daily intranasal dose, taken in the morning due to the peptide's more activating profile, for a defined period of approximately 10–14 days, followed by a break of several weeks before potential re-initiation. This mirrors the structure used in Russian post-stroke rehabilitation protocols [10] and several chronic animal studies which typically lasted one to two weeks, rather than months [13].

This is not a rigid rule established from controlled human trials – rather, it is a pattern emerging from a review of the entire available research base. Anyone using Semax outside of medical supervision should treat this as a general framework, not a precise prescription, and pay close attention to their own body's response rather than assuming a fixed schedule will work identically for everyone.

Does the frequency have to change depending on the purpose?

It's reasonable to assume so, although no study has directly tested different frequencies against each other for different purposes.

Stroke recovery protocols, involving more significant neurological injury, utilised higher total doses delivered in structured 10-day courses [1], [10] – a more intensive schedule than that typically employed in lower-dose cognitive and behavioural studies [2], [6]. This suggests that more demanding clinical aims were paired with more frequent, intense dosing regimens, while lighter cognitive support applications usually involved smaller, simpler dosing.

For someone using Semax for general cognitive purposes, rather than treating a specific medical condition, there is no evidence to suggest that dosing more frequently than once a day would add significant benefits. Given the bell-shaped dose-response pattern observed in some studies [4], more does not automatically mean better. Starting with a simple once-a-day regimen and adjusting based on observed personal response is a more sensible approach than assuming a more aggressive schedule would yield proportionally better results.

Disclaimer

This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a dosing instruction for self-administration. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Dosage information presented here reflects amounts studied or used in published research and clinical practice, and is not intended to guide or encourage self-administration. There is no officially validated dosing protocol for humans outside of Russian clinical practice. Additional, well-designed clinical trials are needed to establish safe and effective human dosages more broadly.

References

[1] Gusev, E. I., Skvortsova, V. I., Myasoedov, N. F., Nezavibatko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). Effectiveness of semax in acute period of hemispheric ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 97(6), 26–34. PMID: 11517472

[2] Inozemtsev, A. N., Agapitova, A. E., Bokieva, S. B., Glazova, N. Yu., Levitskaia, N. G., Kamenskiĭ, A. A., & Miasoedov, N. F. (2013). Opposite Semax influence on conditioning and functional disturbances of avoidance responses in rats. Journal of Higher Nervous Activity named after I.P. Pavlov, 63(6), 711–718. https://doi.org/10.7868/s0044467713060063

[3] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioural Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28

[4] Iasnetsov, Vik. V., & Voronina, T. A. (2010). Antihypoxic and antiamnesic effects of mexidol and Semax. Experimental and Clinical Pharmacology, 73(4), 2–7. PMID: 20486550

[5] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108

[6] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745

[7] Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z

Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 97(Suppl 1), 82–86. https://doi.org/10.1111/j.1471-4159.2006.03658.x

[9] Levitskaya, N. G., Sebentsova, E. A., Andreeva, L. A., Alfeeva, L. Yu., Kamenskii, A. A., & Myasoedov, N. F. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neuroscience and Behavioural Physiology, 34(4), 399–405. https://doi.org/10.1023/b:neab.0000018752.59465.28

Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68

[11] Polunin, G. S., Nurieva, S. M., Baiandin, D. L., Sheremet, N. L., & Andreeva, L. A. (2000). Evaluation of the therapeutic effect of the new Russian drug semax in optic nerve disease. Journal of Ophthalmology, 116(1), 15–18. PMID: 10741256

[12] Yasenyavskaya, A. L., Samotrueva, M. A., Tsibizova, A. A., Bashkina, O. A., Myasoedov, N. F., & Andreeva, L. A. (2021). The influence of Selank on the level of cytokines under the conditions of „social” stress. Current Reviews in Clinical and Experimental Pharmacology, 16(2), 162-167. https://doi.org/10.2174/1574884715666200704152810

[13] Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024